FDA Panel Recommends Approval Of GRAIL's Galleri Multi-Cancer Early Detection Test

GRAIL's Galleri multi-cancer early-detection test received a favorable FDA panel vote, advancing it one step closer to potential regulatory approval. The vote materially de-risks the product's path to market and is a positive catalyst for GRAL, although final FDA approval remains pending.